Polyiclc
Mucosal Melanoma
Fred Hutchinson Cancer CenterPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 81/ 100
Competitive context
32 Active assets in the Mucosal Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Melanoma Institute Australia | Phase 3 | BB |
Tyrosinase Peptide University of Southern California | Phase 3 | BB |
INTERFERON ALFA-2B Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | B |
Ifa Craig L Slingluff, Jr | Phase 2 | B |
Carboplatin Sun Yat-sen University | Phase 3 | B |
View all 50 →
Same molecule, other indications
Polyiclc is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →